Letter to the EditorPersonalized regimen for PCSK9 inhibitors: A therapeutic option that maintains efficacy and reduces costs
References (5)
- et al.
Cost-effectiveness of PCSK9 inhibition in addition to standard lipid-lowering therapy in patients at high risk for vascular disease
Int J Cardiol
(2018) - et al.
PCSK9 Inhibitors: Economics and Policy
J Am Coll Cardiol
(2017)
There are more references available in the full text version of this article.
Cited by (7)
Lipoprotein(a) in familial hypercholesterolemia: Tips from family history
2021, Revista Portuguesa de CardiologiaEvolocumab improves intima media thickness regression in HeFH subjects on lipoprotein apheresis
2020, Nutrition, Metabolism and Cardiovascular DiseasesPCSK9 Inhibitors in a German Single-Center Clinical Practice: Real-World Treatment of Patients at High Cardiovascular Risk Over 68 Weeks
2021, American Journal of Cardiovascular DrugsA large Italian cohort on proprotein convertase subtilisin/kexin type 9 inhibitors
2020, European Journal of Preventive CardiologyPCSK9 Inhibitors’ New Users: Analysis of Prescription Patterns and Patients’ Characteristics from an Italian Real-world Study
2020, Clinical Drug Investigation
Funding Sources: No financial support was received.
Financial disclosures: The authors have no conflicts of interest to declare.
© 2018 National Lipid Association. All rights reserved.